touchCONGRESS HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?

In this interview, Gabriel Hortobagyi answers the following questions:

• The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

Prof. Gabriel Hortobagyi is Professor in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center. His oncology career of more than 40 years has focused on clinical and translational research, teaching and mentoring the next generation of scientists, and academic leadership. He is Past President of the American Society of Clinical Oncology (ASCO) and is one of the world’s leading authorities on the management of breast cancer. Professor Hortobagyi has been the recipient of numerous prestigious awards. He has over 1100 full-length publications in peer-reviewed journals and over 140 book chapters to his credit.

Prof. Hortobagyi has served on various task forces and committees of the American Society of Clinical Oncology, served on the Board of Directors, and in 2005 was elected President. He served as President of the International Society of Senology; as a board member for the International Association for Breast Cancer Research; as a member of the U.S. National Committee for the International Union Against Cancer, the National Cancer Institute’s Breast Cancer Progress Review Group, and the Integration Panel of the Breast Cancer Research Program of the Department of Defense. In addition, Professor Hortobagyi chaired the Steering Committee of the Breast Health Global Initiative, the Health Advisory Board of the Susan G. Komen Breast Cancer Foundation, the NCI’s Operational Efficiency Working Group and the Breast Cancer Steering Committee. Professor Hortobagyi was Chair of the Southwest Oncology Group Breast Committee until June 2017 and is chair of the Executive Board of Scientific Advisors of The Breast Cancer Research Foundation.

Prof. Gabriel Hortobagyi  discloses:  Consultant to Novartis in the development of the BOLERO-2, MONALEESA-2 and NATALEE clinical trials.

In this interview, Joan Albanell answers the following questions:

• The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

Prof. Joan Albanell is the head of Medical Oncology at Hospital del Mar (Barcelona). His thesis work was conducted in 1995 and 1996 at the Sloan-Kettering Institute and focused on early studies of telomerase in human cancers. Upon his return to Spain, he worked as a clinician and researcher in three university hospitals in Barcelona (Vall d’Hebron, Clinic and currently at Hospital del Mar). In 2007, he was appointed Director of the Cancer Research Program at Hospital del Mar Research Institute (IMIM). He is Professor of Oncology at the Universitat Pompeu Fabra. The focus of his research over the past 15 years has been the preclinical and clinical study of novel anticancer drugs and their mechanisms of action and resistance. Prof. Albanell is a founder member of the Spanish group of breast cancer research group (GEICAM) and coordinator of the GEICAM Scientific Committee. Since 2017 he has been the Coordinator of Breast Cancer Research within CIBERONC (Network of National Research Groups). In late 2018, he was appointed Director of Oncology (CIOCC) at HM Delfos in Barcelona. His current work focuses on clinical trials in breast cancer, mainly in HER2 positive disease, and in translational research on markers of response and mechanisms of resistance to novel therapies against HER2 positive breast cancer. He is author of more than 210 peer-reviewed articles, with more than 9000 citations.

Prof. Joan Albanell discloses: Honoraria received from Roche, Pfizer, Amgen, Merck Sharp & Dohme, Novartis, Genomic Health, Palex and Seattle Genetics.  Financial support received from Roche, Amgen, Genentech, Pfizer, Merck Sharp & Dohme, Seattle Genetics. Royalties received from Biocartis

In this interview, Sibylle Loibl answers the following questions:

• The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

Prof. Sibylle Loibl, MD, PhD, is the Chief Executive Officer and Chair of the German Breast Group (GBG), one of the leading study groups worldwide. She devotes the majority of her time to clinical trial research at the GBG and at her clinical affiliations: the University of Frankfurt, and Oncology Bethanien in Frankfurt.

Prof. Loibl is an associate professor at the University of Frankfurt. She graduated from the University of Heidelberg and completed her fellowship and residency as a gynaecologist and obstetrician at the University of Heidelberg and Frankfurt.

Prof. Loibl is internationally renowned in the fields of neoadjuvant breast cancer, breast cancer during pregnancy, and breast cancer in young women. She developed the translational research division within the GBG and has led numerous translational projects as well as research projects founded by the EU Commission. She has led and participated in more than 100 national and international clinical trials in the field of breast cancer.

In 2014, she joined the Executive Board of the Breast International Group (BIG). As a medical expert, she serves on several international steering committees, translational research committees, and independent data monitoring committees.

Prof. Loibl has co-authored almost 300 MEDLINE-listed scientific papers, in addition to more than 200 original and peer-reviewed articles, as well as 30 books or book chapters, and she has actively contributed to more than 200 national and international congresses. She is an active member of numerous national and international organizations such as the American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO).

Prof. Sibylle Loibl discloses:  Honoraria received by my institution from AbbVie, Amgen, AstraZeneca, Celgene,Daiichi, Novartis, Pfizer, PRIME, Roche, Seattle Genetics, Teva and Vifor. Research grants received by my institution from ABGSG, AbbVie, Amgen, AstraZeneca, BIG, Celgene, Cepheid, Myriad, NSABP, Novartis, Pfizer, Roche, Teva and Vifor.

In this interview, Mario Campone answers the following questions:

• The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

In this interview, Guiseppe Curigliano answers the following questions:

• The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

In this interview, Stephen Johnston answers the following questions:

• Watch internationally renowned breast cancer clinicians discuss the latest data from the European Society for Medical Oncology (ESMO) Breast Cancer Congress, in Berlin, Germany, 2–4 May 2019, and consider what the findings may mean for global and regional clinical practice.
• How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
• What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
• Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
• Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
• Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

Prof. Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012, and is currently Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden.

He graduated in 1983 from Trinity College at Cambridge University, and in 1986 from the Medical School at the University of Newcastle-upon-Tyne. He trained in general medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in medical oncology at The Royal Marsden. He gained his PhD from The Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist in the Breast Unit at The Royal Marsden in 1997.

He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase 2/3 trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors.

He has published over 250 breast-cancer-related articles in peer-reviewed journals, and is a regular invited lecturer at national and international meetings. He is a member of several scientific committees and advisory boards, a prior faculty member at the American Society for Clinical Oncology, a current member of San Antonio Breast Cancer Symposium abstract review committee, and serves as Deputy/Associate Editor for the international journals Breast Cancer Research and Clinical Breast Cancer.

Prof. Stephen Johnston discloses:  Consultancy for Eli Lilly, AstraZeneca, Novartis and Puma Biotechnology. Member of the speaker bureau for both Pfizer and Novartis.  Institutional research funding from Pfizer.